Innovative Strategies for Hypoxic‐Tumor Photodynamic Therapy

Li, Xingshu; Kwon, Nahyun; Guo, Tian; Liu, Zhuang; Yoon, Juyoung

doi:10.1002/anie.201805138

Cited by 937 publications

(630 citation statements)

References 104 publications

Supporting

Mentioning

600

Contrasting

Order By: Relevance

“…As a result, combined PTT–PDT has been widely investigated. PTT can increase oxygen in the tumor by improving blood flow, and increase the cellular uptake efficiency of photosensitizers, resulting in more effective PDT . Photosensitizers could be loaded on 2D nanomaterials to increase dispersibility, enhance accumulation in tumors and achieve on‐demand release.…”

Section: Nanomaterials For Ptt‐based Synergistic Therapymentioning

confidence: 99%

Two‐Dimensional Nanomaterials for Photothermal Therapy

2020

View full text Add to dashboard Cite

Two‐dimensional (2D) nanomaterials are currently explored as novel photothermal agents because of their ultrathin structure, high specific surface area, and unique optoelectronic properties. In addition to single photothermal therapy (PTT), 2D nanomaterials have demonstrated significant potential in PTT‐based synergistic therapies. In this Minireview, we summarize the recent progress in 2D nanomaterials for enhanced photothermal cancer therapy over the last five years. Their unique optical properties, typical synthesis methods, and surface modification are also covered. Emphasis is placed on their PTT and PTT‐synergized chemotherapy, photodynamic therapy, and immunotherapy. The major challenges of 2D photothermal agents are addressed and the promising prospects are also presented.

show abstract

Section: Nanomaterials For Ptt‐based Synergistic Therapymentioning

confidence: 99%

Two‐Dimensional Nanomaterials for Photothermal Therapy

2020

View full text Add to dashboard Cite

show abstract

“…As a burgeoning cancer tool, phototherapy offers specific spatiotemporal selectivity and minimal invasion into healthy tissues . Phototherapy generally involves the activation of photosensitizers (PSs) under light irradiation to induce cancer cell phototoxicity by generating reactive oxygen species (ROS) (photodynamic therapy, PDT) or heating via nonradiative relaxation pathways (photothermal therapy, PTT) …”

Section: Introductionmentioning

confidence: 99%

Boron Dipyrromethene Nano‐Photosensitizers for Anticancer Phototherapies

Sun

Zhao

Fan

et al. 2019

Small

149

116

View full text Add to dashboard Cite

As traditional phototherapy agents, boron dipyrromethene (BODIPY) photosensitizers have attracted increasing attention due to their high molar extinction coefficients, high phototherapy efficacy, and excellent photostability. After being formed into nanostructures, BODIPY‐containing nano‐photosensitizers show enhanced water solubility and biocompatibility as well as efficient tumor accumulation compared to BODIPY molecules. Hence, BODIPY nano‐photosensitizers demonstrate a promising potential for fighting cancer. This review contains three sections, classifying photodynamic therapy (PDT), photothermal therapy (PTT), and the combination of PDT and PTT based on BODIPY nano‐photosensitizers. It summarizes various BODIPY nano‐photosensitizers, which are prepared via different approaches including molecular precipitation, supramolecular interactions, and polymer encapsulation. In each section, the design strategies and working principles of these BODIPY nano‐photosensitizers are highlighted. In addition, the detailed in vitro and in vivo applications of these recently developed nano‐photosensitizers are discussed together with future challenges in this field, highlighting the potential of these promising nanoagents for new tumor phototherapies.

show abstract

“…[1][2][3][4] In a typical procedure, irradiation of a PS by light induces intersystem crossing (ISC) of the singlet PS to triplet excited state followed by intermolecular energy transfer between triplet excited state of the PS and molecular oxygen yielding highly reactive and cytotoxic singlet oxygen ( 1 O 2 ). [6,7] In this context, organelletargeted and red/near-IR absorbing PSs are highly promising. While hypoxic conditions are already reducing the efficacy of the conventional therapies through upregulation of hypoxia-inducible transcription factors (HIFs), the impact on PDT is more pronounced as 1 O 2 generation is highly dependent on oxygen.…”

Section: Introductionmentioning

confidence: 99%

Mitochondria‐Targeting Selenophene‐Modified BODIPY‐Based Photosensitizers for the Treatment of Hypoxic Cancer Cells

et al. 2019

View full text Add to dashboard Cite

Two red-absorbing, water-soluble and mitochondria (MT)targeting selenophene-substituted BODIPY-based photosensitizers (PSs) were realized (BODÀ Se, BODÀ SeÀ I), and their potential as photodynamic therapy (PDT) agents were evaluated. BODÀ SeÀ I showed higher 1 O 2 generation yield thanks to the enhanced heavy-atom effect, and this derivative was further tested in detail in cell culture studies under both normoxic and hypoxic conditions. BODÀ SeÀ I not only effectively functioned under hypoxic conditions, but also showed highly selective photocytotoxicity towards cancer cells. The selectivity is believed to arise from differences in mitochondrial membrane potentials of healthy and cancerous cells. To the best of our knowledge, this marks the first example of a MT-targeted BODIPY PS that functions under hypoxic conditions. Remarkably, thanks to the design strategy, all these properties where realized by a compound that was synthesized in only five steps with 32 % overall yield. Hence, this material holds great promise for the realization of next-generation PDT drugs for the treatment of hypoxic solid tumors.

show abstract

Innovative Strategies for Hypoxic‐Tumor Photodynamic Therapy

Cited by 937 publications

References 104 publications

Two‐Dimensional Nanomaterials for Photothermal Therapy

Two‐Dimensional Nanomaterials for Photothermal Therapy

Boron Dipyrromethene Nano‐Photosensitizers for Anticancer Phototherapies

Mitochondria‐Targeting Selenophene‐Modified BODIPY‐Based Photosensitizers for the Treatment of Hypoxic Cancer Cells

Contact Info

Product

Resources

About